With the development of the technologies of drug delivery, different forms of inhibitors targeting TRIM6, i.e., shRNAs and neutralizing antibodies, can be internalized into kidney tissues and cells to suppress TRIM6 expression and treat renal fibrosis in patients with kidney diseases. Here, TRIM6 is linked to kidney disorder.